bluuebunny/crossref_metadata_2025_split huggingface dataset:
Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
Authors: Dima Danai , Lopetegui‐Lia Nerea , Ogbue Olisaemeka , Osantowski Bennett , Ullah Fauzia , Jia Xuefei , Song Jung Min , Gastman Brian , Isaacs James , Kennedy Lucy Boyce , Funchain Pauline 
Published: June 2024

AbstractBackgroundBoth immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse, for whom best management is unclear. The aim of our study was to assess the efficacy, and safety of adj anti‐PD1 IO and TT in a real‐world cohort of patients with resected stage III melanoma, and further delineate patterns of recurrence and treatment strategies.MethodsWe retrospectively analyzed 130 patients who received adj therapy (100 anti‐PD1 IO and 30 TT).ResultsAt a median follow‐up of 30 months, median relapse‐free survival (RFS) was 24.6 (95% CI, 17–not reached [NR]) versus 64 (95% CI, 29.5–NR) months for the TT and IO groups, respectively (p = 0.26). Median overall survival (OS) was NR for either subgroup. At data cutoff, 77% and 82% of patients in TT and IO arms were alive. A higher number of grade ≥3 treatment‐related adverse events (AEs) were noted in the IO group (11% vs. 3%), however, a higher proportion of patients permanently discontinued adj therapy in the TT group (43% vs. 11%) due to toxicity. Strategies at relapse and outcomes were variable based on location and timing of recurrence. A significant number of patients who relapsed after adj IO received a second round of IO. Among them, patients who were off adj IO at relapse had superior second median RFS (mRFS2), compared to those who relapsed while on adj IO; mRFS2 was NR versus 5.1 months (95% CI, 2.5–NR), respectively, p = 0.02.ConclusionIn summary, both TT and IO yielded prolonged RFS in a real‐world setting, however, longer follow‐up is needed to determine any potential OS benefit. Adj therapy, particularly TT, may not be as well tolerated as suggested in clinical trials, with lower completion rates (59% vs. 74%) in a real‐life setting. Overall, patients who relapse during adj therapy have poor outcomes, while patients who relapse after discontinuation of adj IO therapy appear to benefit from IO re‐treatment.
Radiofrequency ablation in patients with obstructive hypertrophic cardiomyopathy: An updated comprehensive review and meta‐analysis
Authors: da Silva Menezes Antonio , Sanches Murilo R. , de Oliveira Filho Ernani , de Oliveira Elias J. R. , Oliveira Vinicius M. R. , Moraes Vitor R. Y. 
Published: June 2024

AbstractBackgroundRadiofrequency catheter ablation (RFCA) has emerged as a therapeutic option for surgical myectomy and alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy (HOCM), but its efficacy remains unclear.AimDue to limited research on RFCA for HCM, there is an ongoing attempt to assess its efficacy and safety.MethodsPubMed, Embase, and Scopus were systematically searched for studies assessing the efficacy outcomes for patients with HOCM who underwent RFCA. Mean differences (MDs) with 95% confidence intervals (CIs) were computed using a random‐effects model and heterogeneity was assessed using I2 statistics.ResultsWe included 11 studies comprising 470 patients, of whom 34.6% were female. The mean patient age ranged from 43.7 to 60.7 years. During the follow‐up after RFCA, there was a significant decrease in the left ventricular outflow tract (LVOT) gradient at rest (MD −60.25 mmHg; 95% CI [−70.53;−59.14 mmHg]; p < 0.01) and during stimulation (MD −83.56 mmHg; 95% CI [−100.36;−66.76 mmHg]; p < 0.01). Moreover, RFCA reduced interventricular septum (IVS) thickness (MD −3.61 mm; 95% CI [−5.64; −1.59 mm]; p = 0.01) and New York Heart Association (NYHA) class (MD −1.46; 95% CI [−1.69; −1.24]; p < 0.01).ConclusionsIn patients with HOCM, RFCA was associated with an improved NYHA class, reduced IVS thickness, and decreased LVOT gradient at rest and with stimulation.
Long‐term outcomes after echocardiography versus fluoroscopy‐guided left atrial appendage closure: Is there still a role for a simplified approach?
Authors: Gilhofer Thomas S. , Schweiger Victor , Gehler Mario , Bokemeyer Victoria , Chen Mi , Candreva Alessandro , Würdinger Michael , Di Vece Davide , Templin Christian , Niederseer David , Stähli Barbara E. , Stehli Julia , Gotschy Alexander , Jakob Philipp , Ruschitzka Frank , Binder Ronald , Nietlispach Fabian , Michel Jonathan , Kasel A. Markus 
Published: June 2024

AbstractBackgroundLeft atrial appendage closure (LAAC) represents an alternative to oral anticoagulation for stroke prevention in patients with non‐valvular atrial fibrillation (AF). While transoesophageal echocardiography is the current standard for guiding LAAC procedures, several centers have employed fluoroscopic guidance alone. However, data on long‐term outcomes are lacking.MethodsA total of 536 patients with AF undergoing LAAC and with available data on long‐term follow‐up were included in the retrospective, single‐center analysis. Outcomes of patients undergoing fluoroscopy‐guided LAAC were compared with those undergoing echocardiography guided LAAC. Time‐dependent analysis was performed with the Kaplan–Meier method.ResultsA total of 234 (44%) and 302 (56%) patients were treated with echocardiography and fluoroscopy guidance, respectively. Baseline characteristics did not differ between the two groups. Procedural success rates were high in both groups (97% of fluoroscopy vs. 98% of echocardiography guided procedures; p = 0.92) and rates of relevant peri‐device leaks (p = 0.50) and device‐related thrombus formation (p = 0.22) did not differ between groups. Median clinical follow‐up time was 48 (IQR 19–73) months. Rates of all‐cause mortality (p = 0.15, HR 0.83, CI 0.64–1.07) and stroke (p = 0.076, HR 2.23, CI 0.90–5.54) were comparable among groups.ConclusionLAAC with fluoroscopy guidance alone is equally safe and leads to similar clinical outcome compared to LAAC with additional echocardiography guidance.
1‐Haloalkynes: Privileged Substrates for Gold Catalysis
Authors: Miguélez Rubén , Arto Omar , Rodríguez‐Arias Carlos , González José Manuel , Barrio Pablo 
Published: June 2024

AbstractAlkynes have been the preferred substrates since the early development of gold catalysis at the dawn of this century. Amongst them, 1‐haloalkynes have gained increased interest in recent years due to the versatility offered by these bifunctional entities as well as the identification of unique reaction modes in this already mature research field. Herein, the seminal contributions that resulted in the observed growth in recent years and the most recent developments will be discussed.
The ‘Open’ Site of Lewis Acid Zeolites for Meerwein‐Ponndorf‐Verley‐Oppenauer Reactions in Biomass Catalysis
Authors: Wu Meng , Liu Meng , Guo Pengfei , Lu Tianliang , Wu Zhijie , Luo Wenhao 
Published: June 2024

AbstractHeteroatom zeolites are efficient catalysts for activating oxygenates in Meerwein‐Ponndorf‐Verley‐Oppenauer (MPVO) reactions, due to the unique Lewis acid character of their tetrahedral heteroatom metal sites. Such Lewis acid zeolites, especially heteroatom Beta zeolites, are intensively investigated with increasing attention in the valorization of biomass‐derived oxygenates. Herein, we first briefly review the recent development and advantage of Lewis acid zeolites for MPVO reactions involved in biomass valorization, majorly based on the selected case studies of the most representative heteroatom Beta zeolites. Increasing recognization of the open framework sites as the intrinsic active sites for Lewis acid zeolites in MPVO reactions has been discussed, with static and dynamic viewpoints. Furthermore, the recent progress on the development of characterization technologies applied in recent the state‐of‐the‐art showcases of identification and quantification of open sites, has been assessed, with a special focus on indirect detection using probe molecules and direct detection approaches. Future opportunities and challenges regarding the development of complimentary in situ characterization technologies and in‐depth understanding of the true nature of active sites and correlative mechanisms are examined for the ultimate goal of providing stable MPVO catalysts in biomass valorization.
Spatially Resolved Multicolor Luminescence Tuning on the Single 1D Heterogeneous Microrod
Authors: Lu Changyuan , You Wenwu 
Published: June 2024

AbstractThe spatially resolvable multicolored microrods have potential applications in many fields. However, achieving spatially resolved multicolor luminescence tuning on the microrod with a fixed composition remains a daunting challenge. Herein, a strategy is proposed that allows for the tuning of spatially resolved, multicolored upconversion (UC) luminescence (UCL) along a 1D heterogeneous microrod by modifying the pulse width of an external laser. NaYbF4:1 % Ho is identified as an UCL color‐adjustable material, exhibiting pulse width‐dependent multicolored UCL, resulting in a significant regulation of the red/green (R/G) ratio from 0.1 to 10.3 as the pulse width is varied from 0.1 to 10 ms. Such variability can be ascribed to differences in the number of photons incident upon the microrod throughout the period necessary for the UC process to occur. Additionally, NaYbF4:1 %Tm and NaYF4:20 %Yb,1 %Ho are employed as materials that emit blue and green light, respectively, with their UCL colors largely unaffected by changes in the pulse width. Subsequently, a tip‐modified epitaxial growth method is utilized to integrate both UCL color‐adjustable and non‐adjustable segments within the same microrod. Comparing with single‐color or fixed multicolor microrods, our developed multisegmented emissive color adjustable 1D heterogeneous microrods have unique optical characteristics and can carry more optical information.
Construction of Acyclic Quaternary Carbon Stereocenters via Enantioselective Nickel Catalysis†
Authors: Song Jian , Li Xuening , Long Jinguo , Yang Hua , Fang Xianjie 
Published: June 2024

Comprehensive SummaryThe construction of acyclic quaternary carbon stereocenters, which are ubiquitous in many bioactive compounds, pharmaceuticals and natural products, has been a long persuit in synthetic organic chemistry. Among numerous methods, enantioselective nickel‐catalysis has attracted incremental attention in recent years. This review summarizes the recent development in the asymmetric strategies, research progress, mechanistic investigations for the generation of acyclic quaternary carbon stereocenters via enantioselective nickel catalysis.
Key ScientistsIn 2006, the Zhou group and RajanBabu group realized the nickel‐catalyzed enantioselective hydrovinylation of α‐substituted styrenes and ethylene to construct acyclic quaternary carbon stereocenters (QCSs) by using spiro‐ and binaphthyl phosphoramidite ligands, respectively. In 2016, Watson developed a nickel‐catalyzed Suzuki‐Miyaura arylation to generate acyclic QCSs via chirality transfer reaction. In 2017, the Feng and the Fu group developed nickel‐catalyzed enantioselective conjugated/Michael additions to build acyclic QCSs, respectively. In 2020, the Fang group made the first success in the construction of QCSs by nickel‐catalyzed hydrocyanation of alkenes and allenes. In 2021, Gregory C. Fu and co‐workers disclosed a nickel‐catalyzed enantioselective α‐functionalization of carbonyl compounds that could form acyclic QCSs. At the same time, the Shi group constructed chiral acyclic QCSs via nickel‐catalyzed functionalization of alkenes. In 2023, Kleij and co‐workers applied a new strategy for Ni‐catalyzed regio‐ and enantioselective homoallylic coupling to construct acyclic QCSs. In the same year, Tao and co‐workers demonstrated a novel strategy that is dinickel‐catalyzed enantioselective α‐alkylation of carbonyl compounds with alkyl iodides.
Regulating Built‐in Polar States via Atomic Self‐Hybridization for Fast Ion Diffusion Kinetics in Potassium Ion Batteries†
Authors: Du Hongwei , Zhou Xiaoyun , Li Tao , Zhao Wen , Zhou Dan , Yang Dawei , Wu Tianli , Xu Ying 
Published: June 2024

Comprehensive SummaryPotassium ion batteries (PIBs) are of great interest owing to the low cost and abundance of potassium resources, while the sluggish diffusion kinetics of K+ in the electrode materials severely impede their practical applications. Here, self‐hybridized BiOCl0.5Br0.5 with a floral structure is assembled and used as anode for PIBs. Based on the systematic theoretical calculation and experimental analysis, the unbalance of charge distribution between Cl and Br atoms leads to an enhanced built‐in electric field and a larger interlayer spacing, which can enhance the K+ diffusion. Furthermore, the K+ insertion causes the energetic evolution of polar states in the BiOCl0.5Br0.5 crystal framework, where the dynamic correlation between the K+ and the halogen atoms leads to the formation of hole‐like polarons, which significantly improves the K+ diffusion and reaction kinetics during the charging/discharging process, giving important implications to design the electrode materials with high electrochemical performance by engineering the interaction between electronic structure and interface. Therefore, the BiOCl0.5Br0.5 anode obtains an excellent performance of 171 mAh·g–1 at 1 A·g–1 over 2000 cycles in PIBs.
Visible Light Catalyzed Reductive Cross‐Coupling of α‐CF3‐alkyl Bromide and Alkynyl Bromide†
Authors: Tian Yiqiang , Li Yi , Zhang Chun 
Published: June 2024

Comprehensive SummaryTraditional reduction coupling reactions of two bromides typically rely on transition metal catalysis. Here, we introduce the development of a visible‐light catalytic direct reduction coupling reaction between α‐CF3‐alkyl bromides and alkynyl bromides to access valuable organic frameworks. Our research confirms the excellent compatibility of this reaction with various functional groups, which could be used to modify the substrate with biologically active molecular fragments. Mechanistic investigations, including control experiments, fluorescence quenching studies, and light‐switching experiments, have provided insights into the reaction mechanism. This study paves the way for the application of visible‐light catalysis in diverse synthetic transformations, offering a sustainable and efficient approach to organic synthesis.
Host‐Guest Chemistry and Nonlinear Optical Behaviors of Aluminum Molecular Rings†
Authors: Chen Yi‐Bo , Zhang Cheng‐Yang , Luo Dan , Chen Ran‐Qi , Zhang Jian , Chen Shu‐Mei , Fang Wei‐Hui 
Published: June 2024

Comprehensive SummaryMacrocyclic compounds are of great interest for their ability to capture guest molecules into their cavities. In particular, host‐guest interaction plays a crucial role in the formation of supramolecular compounds. Herein, two host‐guest supramolecular compounds, [Al8(OH)8(L)16]·2HL (HL@AlOC‐166, HL = 4‐Iodobenzoic acid) and [Al8(OH)8(L)8(L1)8]·2DMF (DMF@AlOC‐166, HL1 = isoamyl alcohol), are acquired by introducing different types of guest components based on the internal pore cavities of the aluminum molecular ring [Al8(OH)8(L)16] (AlOC‐166). The inclusion of these guests is attributed to the presence of abundant hydrophilic OH serving as the hydrogen bond donors inward the ring cavity. Host‐guest compounds usually exhibit superior nonlinear optical (NLO) response due to the existence of guest molecules that could change symmetry, dipole moments, charge distributions, etc. Unexpectedly, the AlOC‐166 achieved the best NLO results, although it had no guest molecules inside its molecular ring, which breaks the traditional concept. The reason for this trend can be explained by the difference in intermolecular force rather than intramolecular interaction, mainly related to the amount and strength of π···π and C—I···π interactions in different compounds. This work investigates the effect of host‐guest interaction on NLO, representing a new perspective for designing optical limiting materials.
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Authors: Chung Hyun Cheol , Saada‐Bouzid Esma , Longo Federico , Yanez Eduardo , Im Seock‐Ah , Castanon Eduardo , Desautels Danielle N. , Graham Donna M. , Garcia‐Corbacho Javier , Lopez Juanita , Dutcus Corina , Okpara Chinyere E. , Ghori Razi , Jin Fan , Groisberg Roman , Korakis Iphigenie 
Published: June 2024

AbstractBackgroundNovel treatments are needed for patients with advanced, triple‐negative breast cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The authors report results from the TNBC cohort of the multicohort, open‐label, single‐arm, phase 2 LEAP‐005 study of lenvatinib plus pembrolizumab in patients with advanced solid tumors (ClinicalTrials.gov identifier NCT03797326).MethodsEligible patients had metastatic or unresectable TNBC with disease progression after one or two lines of therapy. Patients received lenvatinib (20 mg daily) plus pembrolizumab (200 mg every 3 weeks; up to 35 cycles). The primary end points were the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1, and safety (adverse events graded by the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0). Duration of response, progression‐free survival, and overall survival were secondary end points.ResultsThirty‐one patients were enrolled. The objective response rate by investigator assessment was 23% (95% confidence interval [CI], 10%–41%). Overall, the objective response rate by blinded independent central review (BICR) was 32% (95% CI, 17%–51%); and, in patients who had programmed cell death ligand 1 combined positive scores ≥10 (n = 8) and <10 (n = 22), the objective response rate was 50% (95% CI, 16%–84%) and 27% (95% CI, 11%–50%), respectively. The median duration of response by BICR was 12.1 months (range, from 3.0+ to 37.9+ months). The median progression‐free survival by BICR was 5.1 months (95% CI, 1.9–11.8 months) and the median overall survival was 11.4 months (95% CI, 4.1–21.7 months). Treatment‐related adverse events occurred in 94% of patients (grade 3, 52%; grade 4, 0%). One patient died due to a treatment‐related adverse event of subarachnoid hemorrhage.ConclusionsThe combination of lenvatinib plus pembrolizumab demonstrated antitumor activity with a manageable safety profile in patients with previously treated, advanced TNBC.
Top advances of the year: Targeted therapy for lung cancer
Authors: Makarem Maisam , Jänne Pasi A. 
Published: June 2024

AbstractThe past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The identification of guideline‐recommended actionable targets has provided the foundation for developing multiple new therapeutic agents. There has been a focus on developing drugs designed to overcome acquired resistance, a limitation of tyrosine kinase inhibitor–based therapy in lung cancer. In addition, there is an emerging trend toward combination therapies for patients in the first‐line setting with the goal of preventing or delaying resistance. Another promising area of development has been the use of antibody–drug conjugates, where there are the initial reports of central nervous system efficacy and activity in patients with genomic alterations. Over the past year, numerous publications and presentations have highlighted multiple therapeutic advances, offering new treatment options for patients with NSCLC. The focus of this review is to summarize the most impactful findings, emphasizing their significance in the evolving treatment landscape for NSCLC. Several landmark trials in lung cancer with practice‐changing clinical implications have been presented and published in 2023. This article reviews a selection of these trials as they relate to early and advanced‐stage oncogene‐driven lung cancer. The ADAURA and ALINA trials, in which targeted therapy given in the adjuvant setting has demonstrated improved clinical outcomes, are reviewed. In the advanced‐stage setting, recent trials in the context of specific oncogene drivers are reviewed, including EGFR, ALK, ROS1, RET, ERBB2 (HER2), BRAF, MET exon 14 skipping (METex14), and KRAS alterations. Also discussed are the results of several trials that have evaluated the use of combination therapies and resistance‐mechanism agnostic treatment strategies.Plain Language Summary

Targeted therapy plays an important role for patients with early and advanced‐stage non–small cell lung cancer carrying specific genetic alterations.
New strategies that combine multiple therapies are now being studied in randomized clinical trials, with the goal of enhancing the effectiveness of targeted therapy for patients with advanced lung cancer.
Data Processing for Predicting DNA Damaging Properties of Complex UV Sources
Authors: Douki Thierry , Millot Océane , Buhot Arnaud 
Published: June 2024

AbstractA growing number of experimental evidence emphasizes that photobiological phenomena are not always the sum of the effect of individual wavelengths present in the emission spectrum of light sources. Unfortunately, tools are missing to identify such non‐additive effects and predict effects of various exposure conditions. In the present work, we addressed these points for the formation of pyrimidine dimers in DNA upon co‐exposure to UVC, UVB and UVA radiation. We first applied a combination index approach to determine whether mixtures of theses UV ranges exhibited additive, inhibitory or synergistic effects on the formation of cyclobutane pyrimidine dimers, (6‐4) photoproducts and Dewar valence isomers. A predictive approach based on an experimental design strategy was then used to quantify the contribution of each wavelength range to the formation of DNA photoproducts. The obtained models allowed us to accurately predict the level of pyrimidine dimers in DNA irradiated under different conditions. The data were found to be more accurate than those obtained with the simple additive approach underlying the use of action spectra. Experimental design thus appears as an attractive concept that could be widely applied in photobiology even for cellular experiments.
Structure and Conformation Determine Gas‐Phase Infrared Spectra of Detergents
Authors: Kirschbaum Carla , Greis Kim , Gewinner Sandy , Schöllkopf Wieland , Meijer Gerard , von Helden Gert , Pagel Kevin , Urner Leonhard H. 
Published: June 2024

AbstractNative mass spectrometry of membrane proteins relies on non‐ionic detergents which protect the protein during transfer from solution into the gas phase. Once in the gas phase, the detergent micelle must be efficiently removed, which is usually achieved by collision‐induced dissociation (CID). Recently, infrared multiple photon dissociation (IRMPD) has emerged as an alternative activation method for the analysis of membrane proteins, which has led to a growing interest in detergents that efficiently absorb infrared light. Here we investigate whether the absorption properties of synthetic detergents can be tailored by merging structural motifs of existing detergents into new hybrid detergents. We combine gas‐phase infrared ion spectroscopy with density functional theory to investigate and rationalize the absorption properties of three established detergents and two hybrid detergents with fused headgroups. We show that, although the basic intramolecular interactions in the parent and hybrid detergents are similar, the three‐dimensional structures differ significantly and so do the infrared spectra. Our results outline a roadmap for guiding the synthesis of tailored detergents with computational chemistry for future mass spectrometry applications.